Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

SHIP1 Inhibition As Novel Therapeutic Approach in Chronic Lymphocytic Leukemia

Veronika Ecker, MSc, Martina Braun, Tanja Neumayer, Markus Muschen, MD, Jürgen Ruland, Maike Buchner, Dr.

Blood (2018) 132 (Supplement 1): 894.

https://doi.org/10.1182/blood-2018-99-117053

Published: 2018

Journal Articles

DUSP1/6 Inhibition Reduces Tumor Cells and Activates Immune Response in Chronic Lymphocytic Leukemia

Martina Braun, Veronika Ecker, MSc, Tanja Neumayer, Markus Muschen, MD, Jürgen Ruland, Maike Buchner, Dr.

Blood (2018) 132 (Supplement 1): 2857.

https://doi.org/10.1182/blood-2018-99-117052

Published: 2018

Journal Articles

CD33/CD3-Bispecific T-Cell Engaging (BiTE®) Antibody Constructs Efficiently Target Monocytic CD14 + hla-DR low IDO + aml-MDSCs

Dimitrios Mougiakakos, Domenica Saul, Martina Braun, Dr., Sehmus Tohumeken, Roman Kischel, MD, Lutteropp Michael, Dr., Cedric E. Dos Santos, Regina Jitschin, PhDMD, Andreas Mackensen, MD

Blood (2017) 130 (Supplement 1): 1363.

https://doi.org/10.1182/blood.V130.Suppl_1.1363.1363

Published: 2017

Journal Articles

Stromal cell–mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling

Regina Jitschin, Martina Braun, Mirjeta Qorraj, Domenica Saul, Katarina Le Blanc, Thorsten Zenz, Dimitrios Mougiakakos

Blood (2015) 125 (22): 3432–3436.

https://doi.org/10.1182/blood-2014-10-607036

Published: 2015

Includes: Supplemental data

Journal Articles

Metabolic Reprogramming of Acute Myeloid Leukemia Blasts By Bone Marrow Stroma Cells

Dimitrios Mougiakakos, Regina Jitschin, Martina Braun, Andreas Mackensen

Blood (2014) 124 (21): 1585.

https://doi.org/10.1182/blood.V124.21.1585.1585

Published: 2014

Journal Articles

CLL-cells induce IDO hi CD14 + HLA-DR lo myeloid-derived suppressor cells that inhibit T-cell responses and promote T Regs

Regina Jitschin, Martina Braun, Maike Büttner, Katja Dettmer-Wilde, Juliane Bricks, Jana Berger, Michael J. Eckart, Stefan W. Krause, Peter J. Oefner, Katarina Le Blanc, Andreas Mackensen, Dimitrios Mougiakakos

Blood (2014) 124 (5): 750–760.

https://doi.org/10.1182/blood-2013-12-546416

Published: 2014

Includes: Supplemental data

NARROW

SHIP1 Inhibition As Novel Therapeutic Approach in Chronic Lymphocytic Leukemia

DUSP1/6 Inhibition Reduces Tumor Cells and Activates Immune Response in Chronic Lymphocytic Leukemia

CD33/CD3-Bispecific T-Cell Engaging (BiTE®) Antibody Constructs Efficiently Target Monocytic CD14 + hla-DR low IDO + aml-MDSCs

Stromal cell–mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling

Metabolic Reprogramming of Acute Myeloid Leukemia Blasts By Bone Marrow Stroma Cells

CLL-cells induce IDO hi CD14 + HLA-DR lo myeloid-derived suppressor cells that inhibit T-cell responses and promote T Regs

Email alerts

ASH Publications

American Society of Hematology

SHIP1 Inhibition As Novel Therapeutic Approach in Chronic Lymphocytic Leukemia

DUSP1/6 Inhibition Reduces Tumor Cells and Activates Immune Response in Chronic Lymphocytic Leukemia

CD33/CD3-Bispecific T-Cell Engaging (BiTE®) Antibody Constructs Efficiently Target Monocytic CD14 + hla-DR low IDO + aml-MDSCs

Stromal cell–mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling

Metabolic Reprogramming of Acute Myeloid Leukemia Blasts By Bone Marrow Stroma Cells

CLL-cells induce IDO hi CD14 + HLA-DR lo myeloid-derived suppressor cells that inhibit T-cell responses and promote T Regs

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only